Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Saved in:
| Title: | Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. |
|---|---|
| Authors: | Hortobagyi, G N (AUTHOR), Stemmer, S M (AUTHOR), Burris, H A (AUTHOR), Yap, Y S (AUTHOR), Sonke, G S (AUTHOR), Paluch-Shimon, S (AUTHOR), Campone, M (AUTHOR), Petrakova, K (AUTHOR), Blackwell, K L (AUTHOR), Winer, E P (AUTHOR), Janni, W (AUTHOR), Verma, S (AUTHOR), Conte, P (AUTHOR), Arteaga, C L (AUTHOR), Cameron, D A (AUTHOR), Mondal, S (AUTHOR), Su, F (AUTHOR), Miller, M (AUTHOR), Elmeliegy, M (AUTHOR), Germa, C (AUTHOR) |
| Source: | Annals of Oncology. Nov2019, Vol. 30 Issue 11, p1842-1842. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1093/annonc/mdz215 |
